This is the authors' abstract. We don't add key points for this paper.
Influenza A hemagglutinin (HA), neuraminidase, and/or M2e-containing virus-like particles (VLPs) induce immune responses that contribute to protection against multiple influenza A virus subtypes. In this study, we investigated the protective efficacy of influenza A/H1H3 VLPs against influenza B virus infections (B/Colorado/06/2017 and B/Malaysia/2506/2004, Victoria lineage) in mice. A/H1H3 VLP immunization elicited protection against lethal challenge infections with both B/Colorado and B/Malaysia, significantly reducing lung viral loads and ensuring 100% survival of immunized mice. Sera from A/H1H3VLP-immunized mice recognized inactivated B/Colorado and B/Malaysia virus antigens and enhanced Fc receptor-mediated antibody-dependent cellular cytotoxicity (ADCC) responses. Notably, immune sera reacted with HA, HA1, and HA2 antigens from both B/Colorado and B/Malaysia viruses. A/H1H3VLP immunization also induced lung IgG and IgA antibody responses against HA, HA1, and HA2 of both B viruses, as well as antibody-secreting cell responses (ASC), germinal center B (GC B) responses, and CD4+ T cell responses. Additionally, A/H1H3VLP immunization significantly suppressed pro-inflammatory cytokines responses (IFN-γ, IL-6). These results suggest that A/H1H3 VLP hold promise as a candidate for a universal influenza vaccine capable of providing cross-protection against influenza B virus infection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: